Evidence map›Paper›PMID 42545321›Full record

ArticleProblemy endokrinologii2026

[Safety Management of Incretin-Based Obesity Therapy: Expert Consensus on the Use of Semaglutide and Tirzepatide].

E A Troshina, M B Antsiferov, A S Ametov, I G Bakulin, G R Galstyan, T N Markova, T I Romantsova, N V Mazurina, O M Koteshkova

Abstract readConsensus StatementEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Problemy endokrinologii, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

E A TroshinaEndocrinology Research Centre.
M B AntsiferovEndocrinological Dispensary.
A S AmetovRussian Medical Academy of Continuing Professional Education.
I G BakulinSt. Petersburg State University.
G R GalstyanEndocrinology Research Centre.
T N MarkovaRussian University of Medicine.
T I RomantsovaRussian Medical Academy of Continuing Professional Education.
N V MazurinaEndocrinology Research Centre.
O M KoteshkovaEndocrinological Dispensary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

On December 3, 2025, a meeting of the expert working group was held in Moscow. The discussion focused on the safety and personalized use of tirzepatide (Tirzetta®) and semaglutide (Velgia® eco) in patients with overweight and obesity. Following the meeting, a consensus position was developed on the optimal use of incretin receptor agonists in real-world clinical practice.

Indexed as

Glucagon-Like PeptidesIncretinsObesityHumansSemaglutideTirzepatideGlucagon-Like PeptidesIncretinsSemaglutideTirzepatide

Identifiers

PMID42545321
PMCPMC13474367

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.